By comparison with agar dilution results, the E test was investigated for the ability to detect high-level aminoglycoside (gentamicin and streptomycin), ampicillin, and vancomycin resistance among strains representing six enterococcal species. For ampicillin and vancomycin, disk diffusion results also were obtained. No false high-level aminoglycoside resistance occurred, and no false gentamicin susceptibility was noted. With the high-range streptomycin E test (2,048 jig), 24% of the 38 resistant strains were falsely susceptible. However, these discordances could likely be reconciled by adjustments in incubation duration and by using broth microdilution rather than agar screen breakpoint criteria, or by using the lower-range (1,024-p,g) Combination therapy with a cell wall-active agent (i.e., ampicillin, penicillin, or vancomycin) and an aminoglycoside (gentamicin or streptomycin) is recommended for serious enterococcal infections such as endocarditis (11). Acquired resistance to these antimicrobial agents, which abrogates their effectiveness as components of therapy, is being encountered with increasing prevalence (4, 7, 9, 11, 12) . Therefore, any enterococcal isolate for which dual therapy is being considered must be monitored for resistance to these agents. The E test (AB Biodisk, Solina, Sweden), a susceptibility testing technique that combines disk-agar diffusion convenience with the precision of quantitative results provided by broth and agar dilution methods, has substantial potential as a means for detecting resistance in enterococci. Briefly, the E test consists of an impervious strip impregnated with a continuous antimicrobial gradient. As is done for disk diffusion testing, the strip is applied to the surface of a Mueller-Hinton agar plate that has been freshly inoculated with the test organism. After incubation at 35°C, the MIC is read at the intersection of growth and the MIC scale of the strip (1, 2).
Combination therapy with a cell wall-active agent (i.e., ampicillin, penicillin, or vancomycin) and an aminoglycoside (gentamicin or streptomycin) is recommended for serious enterococcal infections such as endocarditis (11) . Acquired resistance to these antimicrobial agents, which abrogates their effectiveness as components of therapy, is being encountered with increasing prevalence (4, 7, 9, 11, 12) . Therefore, any enterococcal isolate for which dual therapy is being considered must be monitored for resistance to these agents. The E test (AB Biodisk, Solina, Sweden), a susceptibility testing technique that combines disk-agar diffusion convenience with the precision of quantitative results provided by broth and agar dilution methods, has substantial potential as a means for detecting resistance in enterococci. Briefly, the E test consists of an impervious strip impregnated with a continuous antimicrobial gradient. As is done for disk diffusion testing, the strip is applied to the surface of a Mueller-Hinton agar plate that has been freshly inoculated with the test organism. After incubation at 35°C, the MIC is read at the intersection of growth and the MIC scale of the strip (1, 2) .
This study investigated the ability of vancomycin, ampicillin, high-content gentamicin, and high-content streptomycin E test strips to accurately detect enterococcal resistance to these antimicrobial components of combination therapy. Results were compared with those obtained by agar dilution. Additionally, susceptibility testing to ampicillin and vancomycin were also done by disk-agar diffusion. Inocula 1, 024 and 0.125 to 2,048 ,ug/ml). Unless otherwise stated, E tests were inoculated, incubated, and read according to the manufacturer's recommendations. A common inoculum used for the E test was also used for inoculation in ampicillin and vancomycin agar dilution and disk agar diffusion tests performed according to recommended procedures (13, 14) . Mueller-Hinton agar (Difco Laboratories, Detroit, Mich.) supplemented with gentamicin or streptomycin (range, 250 to 2,000 ,ug/ml) were used to establish high-level aminoglycoside resistance as described previously (17) . Cefinase disks (BBL) were used to test all isolates for ,B-lactamase production (12 (17) , E test MICs for four of these strains changed to >2,048 ,ug/ml, one increased from 768 to 1, 536 ,ug/ml, and the other four MICs remained unchanged (one at 1,024 and three at 2,048 p,g/ml). Similar difficulties were reported by Sanchez et al. (22) . In their study, 9 (17%) of 52 strains for which streptomycin agar MICs were >2,000 ,ug/ml gave E test MICs <2,048 ,ug/ml. False streptomycin susceptibility is a problem commonly encountered with other streptomycin screening methods and, in some instances, appears to be strain related (10, 17) . Therefore, whether recalibration of the high-range (2,048 ,ug) strip (22) would resolve false susceptibility is uncertain. Alternatively, the currently available strip could be used with the interpretive breakpoint of >1,000 ,ug/ml proposed by NCCLS for broth microdilution screens being applied, rather than the 2,000-,ug/ml breakpoint proposed for agar screens (15). With the broth criteria, 37 of 38 (97%) of the streptomycinresistant strains would have been correctly detected after 48 h of incubation. Another option would be to use the lowerrange (1,024 p,g) strip and classify any strain for which the MIC was >1,024 ,ug/ml as resistant. In our study, such an approach resulted in all 38 streptomycin-resistant strains being detected at 24 h (Table 1) .
Ampicillin E test and disk-agar diffusion results obtained with resistant and susceptible strains, as determined by agar dilution, are shown in (Table 2 ).
The difficulty that disk diffusion has detecting truly intermediate strains has been well documented, and the problem does not seem to be easily resolvable (20, 23 All six of the highly vancomycin-resistant (MIC, .256 ,ug/ml) enterococci were detected by E test ( Table 2) . The E test MIC for one strain was 64 ,ug/ml at 24 h, but the strain showed an inner haze of growth in the inhibition zone and the MIC increased to 256 ,ug/ml at 48 h. Similarly, previous studies with a limited number of strains reported that the E test successfully detected vancomycin resistance, but the actual level of resistance of these isolates was not stated (8, 21) . Also (shown in Table 2 ), false susceptibility by disk diffusion did not occur with this organism group. All six isolates gave 6-mm zones; four showing good growth and two exhibiting a lesser haze of growth up to the disk.
In summary, E tests for gentamicin, streptomycin, ampicillin, and vancomycin provide a reliable testing approach for identifying enterococcal resistance to these components of combination therapy. The false susceptibility encountered with streptomycin is not unexpected, as similar problems exist with other screening methods (17) . Furthermore, the problem with the high-content (2,048-,ug) strip appears to be resolvable by increasing incubation to 48 h for strains giving borderline results and by using broth microdilution (MIC, >1,000 gg/ml) rather than agar screen (MIC, >2,000 ,ug/ml) interpretive criteria. Alternatively, the low-content (1,024-,ug) strip could be used. The E test is as reliable as disk diffusion for ampicillin testing. However, whether the potential advantage over disk testing of providing the level of resistance will be realized must await more extensive comparisons that use a greater number of strains with MICs in the 8-to 128-,ug/ml range. The E test appears to be more sensitive than disk diffusion for detecting strains intermedi-ate to vancomycin, but for these strains, and those exhibiting low-level resistance, disk diffusion and E test inhibition zones must be inspected and interpreted with extreme caution. Finally, given that the reliability of the E test for detecting resistance to anti-enterococcal agents compares favorably with results reported for other commercially available methods (10, 17, 24) , the decision for use in a particular laboratory should be based on convenience, cost, testing frequency, and satisfaction with currently used methods.
